Home Latest Articles
Latest Articles
  • Fang QIAN, Anwei DAI
    World Clinical Drug. 2026, 47(2): 157-163.
    Objective

    To investigate the efficacy of Huatan Huoxue decoction on multiple myeloma(MM) of phlegm-stasis obstruction type and its influence on secreted frizzled related protein(SFRP) 3 and glucose regulatory protein(GRP) 78.

    Methods

    The patients with MM admitted to Lianshui county central hospital from January 2022 to December 2024 were selected as the research subjects. They were randomly divided into the observation group(62 cases, treated with chemotherapy+ilarradine+Huatan Huoxue decoction) and the control group(61 cases, treated with chemotherapy+ilarradine) using the simple random method. Both groups were treated continuously for 3 cycles. The main indicator of this study was the clinical total effective rate. The secondary indicators included the levels of SFRP3, GRP78 and inflammatory factors after 1 and 3 cycles of treatment, as well as the visual analogue scale(VAS) for pain, Karnofsky performance status(KPS), and activity of daily living(ADL) scale after 3 cycles of treatment. The safety indicator was the incidence of adverse reactions.

    Results

    The total effective rate of the observation group was significantly higher than that of the control group(93.55% vs. 80.33%, P<0.05). After 1 and 3 cycles of treatment, the serum levels of SFRP3 and GRP78 in both groups were lower than those before treatment(P<0.05), and the levels in the observation group were lower than those in the control group(P<0.05). The serum levels of interleukin(IL)-6, IL-17 and transforming growth factor-β in both groups were lower than those before treatment(P<0.05), and the levels in the observation group were lower than those in the control group(P<0.05). After 3 cycles of treatment, the VAS scores of both groups were lower than those before treatment(P<0.05), and the score of the observation group was lower than that of the control group(P<0.05). The KPS and ADL scores of both groups were higher than those before treatment(P<0.05), and the scores of the observation group were higher than those of the control group(P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05).

    Conclusion

    The formula for resolving phlegm and promoting blood circulation can help alleviate symptoms, delay disease progression, improve SFRP3, GRP78 and inflammatory factors levels, withoutt increasing the incidence of adverse reactions in patients with phlegm stasis obstruction type MM.

  • Yingwei BAI, Hailin YANG, Qiao HONG
    World Clinical Drug. 2026, 47(2): 164-170.
    Objective

    To investigate the adjuvant therapeutic efficacy and safety of octreotide in liver cirrhosis complicated by esophagogastric variceal bleeding(EGVB).

    Methods

    Patients with liver cirrhosis complicated by EGVB admitted to our hospital from January 2023 to January 2025 were enrolled as research subjects and divided into a control group and a study group. All subjects received acute-phase management and conventional treatment, while the study group was additionally given octreotide. The observation course for both groups was 1 week. Before and after treatment, the hemostatic efficacy, platelet count(PLT), prothrombin time(PT), activated partial thromboplastin time(APTT), fibrinogen(FIB), splenic vein diameter(SVD), splenic venous flow(SVF), portal vein diameter(PVD), portal vein blood flow(PVF), serum levels of von Willebrand factor(vWF) and soluble P-selectin, as well as the incidence of adverse reactions were compared between the two groups.

    Results

    After treatment, the total effective rate of hemostasis in the study group was significantly higher than that in the control group(P<0.05). The levels of PLT and FIB in the study group were higher than those in the control group(P<0.05), while the levels of PT, APTT, SVD, SVF, PVD, PVF, vWF and soluble P-selectin were lower than those in the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).

    Conclusion

    Octreotide, as an adjuvant therapy for patients with liver cirrhosis complicated by EGVB, can further improve hemostatic efficacy, effectively increase PLT levels, ameliorate coagulation function and portal hemodynamic status, and regulate the levels of vWF and soluble P-selectin with good safety.

  • Zhenzhen ZHANG, Jiali LI, Chunping GUO
    World Clinical Drug. 2026, 47(2): 171-177.
    Objective

    To explore the effect of the phlegm-resolving, lung-regulating and asthma-relieving decoction as an adjuvant therapy for acute exacerbation of chronic obstructive pulmonary disease(AECOPD) with phlegm-heat accumulation in the lung syndrome and its influence on complement C3, C4 and blood gas indicators.

    Methods

    A total of 120 patients diagnosed with AECOPD with phlegm-heat accumulation in the lung syndrome at Linquan ccounty people's hospital from January 2022 to January 2025 were selected as the research subjects and divided into the observation group and the control group, with 60 cases in each group. Both groups were given conventional western medicine treatment, and the observation group additionally received phlegm-resolving, lung-regulating and asthma-relieving decoction as an adjuvant treatment. The clinical efficacy, C3, C4, blood gas indicators, pulmonary function indicators, and traditional Chinese medicine(TCM) syndrome scores before and after treatment were compared between the two groups.

    Results

    The total effective rate of the observation group was higher than that of the control group(93.33% vs. 80.00%, P<0.05). After treatment, the levels of C3, C4, blood oxygen saturation and partial pressure of oxygen in both groups were higher than those before treatment(P<0.05), and those in the observation group were higher than those of the control group(P<0.05). The levels of partial pressure of carbon dioxide in both groups were lower than those before treatment(P<0.05), and the observation group was lower than that of the control group(P<0.05). After treatment, the levels of forced expiratory volume in one second, forced vital capacity and their ratio in both groups were higher than those before treatment(P<0.05), and those in the observation group were higher than those of the control group(P<0.05). The TCM symptom score of the observation group was lower than that of the control group(P<0.05). There was no statistically significant difference in adverse reactions between the two groups(P>0.05).

    Conclusion:

    Phlegm-resolving, lung-regulating and asthma-relieving decoction as an adjuvant therapy for the AECOPD with phlegm-heat accumulation in the lung syndrome can improve the therapeutic effect and the levels of C3, C4 and blood gas indicators in patients, without increasing the risk of adverse reactions.

  • Lina CHENG, Xuke SI, Dongping ZHANG
    World Clinical Drug. 2026, 47(2): 178-183.
    Objective

    To observe the clinical efficacy of caffeine citrate combined with budesonide inhalation in the treatment of respiratory distress syndrome(RDS) in premature infants.

    Methods

    The clinical data of 175 premature infants with RDS admitted to our hospital from January 2021 to March 2024 were retrospectively analyzed. They were divided into two groups according to different treatment plans: the control group(n=86) received conventional treatment, and the study group(n=89) received additional treatment with caffeine citrate combined with budesonide inhalation on the base of conventional therapy. The clinical indicators, lung function, blood gas indicators, inflammatory factors, and complications were compared between the two groups.

    Results

    The rates of tracheal intubation within 72 hours, weaning failure, the secondary use of pulmonary surfactant, the incidence of bronchopulmonary dysplasia, and the incidence of feeding intolerance in the study group were lower than those in the control group, with statistically significant differences(P<0.05). After treatment, the first-second forced expiratory volume, forced vital capacity, tidal volume, arterial partial pressure of oxygen, and arterial partial pressure of oxygen/inspired oxygen volume fraction in both groups were better than those before treatment(P<0.05), and the study group was better than the control group(P<0.05). After treatment, the arterial partial pressure of carbon dioxide, interleukin-6, and tumor necrosis factor-α in both groups were lower than those before treatment(P<0.05), and the study group was lower than the control group(P<0.05).

    Conclusion:

    Caffeine citrate combined with budesonide inhalation as an adjunctive treatment for RDS in premature infants can reduce the rates of tracheal intubation within 72 hours, weaning failure, the secondary use of pulmonary surfactant, and improve lung function, blood gas indicators, regulate inflammatory factors, and reduce the incidence of bronchopulmonary dysplasia and feeding intolerance.

  • Qinghuan LI, Haifeng LI, Ling ZHANG, Jiali ZHU, Zonglu LI, Xiaona TONG
    World Clinical Drug. 2026, 47(2): 184-197.
    Objective

    To systematically evaluate the clinical efficacy and safety of novel oral factor Ⅹa inhibitors(such as rivaroxaban, apixaban, edoxaban, etc.) in the treatment of middle-aged and elderly patients with pulmonary embolism, to provide evidence-based references for the clinical application of such drugs.

    Methods

    The databases of CNKI, Wanfang Data, VIP, PubMed, Cochrane Library, Web of Science, and Embase were searched by computer to collect randomized controlled trials(RCTs) on the treatment of pulmonary embolism in middle-aged and elderly patients with novel oral factorⅩa inhibitors. The retrieval time limit for all databases was from the establishment of the databases to December 2024. After two researchers independently screened the literature, extracted the data, and evaluated the bias risks of the included studies, the RevMan 5.4 software was used for meta-analysis.

    Results

    A total of 28 RCTs were included, involving 73,764 patients. The medications in the experimental group included novel oral factor Ⅹa inhibitors such as rivaroxaban, apixaban, and edoxaban. The results of the meta-analysis showed that, compared with traditional anticoagulant drugs, novel oral factor Ⅹa inhibitors could significantly improve the clinical effective rate[odds ratio(OR)=1.68, 95% confidence interval·(CI): 1.32—2.15, P<0.001], and there was no significant increase in the risk of bleeding (clinically relevant non-major bleeding OR=0.97, 95%CI: 0.78—1.21, P=0.77; minor bleeding OR=1.21, 95%CI: 0.91—1.38, P=0.29).

    Conclusion

    Current evidence shows that novel oral factor Ⅹa inhibitors have significant clinical efficacy in the treatment of middle-aged and elderly patients with pulmonary embolism, and compared with traditional anticoagulant drugs, they do not significantly increase the risk of bleeding.

  • Yulan ZHANG, Ge YUAN, Xingjing LI
    World Clinical Drug. 2026, 47(2): 198-202.
    Objective

    To analyze the pathogen distribution and drug resistance in elderly patients with community-acquired pneumonia complicated with type 2 diabetes mellitus(T2DM).

    Methods

    A retrospective analysis was conducted on pathogen distribution in 171 elderly patients with community- acquired pneumonia complicated with T2DM in the hospital, and the drug resistance was analyzed in combination with drug sensitivity.

    Results

    A total of 182 strains of pathogenic bacteria were detected, including 108 strains(59.34%) of Gram-negative bacteria, 32 strains(17.58%) of Gram-positive bacteria, and 42 strains(23.08%) of fungi. The predominant Gram-negative bacteria were Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, and Escherichia coli. The Gram-positive bacteria were Staphylococcus aureus, Enterococcus faecium, and Enterococcus faecalis. The predominant fungi were Candida albicans, Candida glabrata, and Candida tropicalis. Drug resistance analysis revealed the overall resistance rate of Klebsiella pneumoniae and Acinetobacter baumannii to antibiotics was low, Pseudomonas aeruginosa was resistant to ceftazidime, Escherichia coli was resistant to cefepime, ceftazidime, and levofloxacin. Gram-positive bacteria were resistant to erythromycin and penicillin.

    Conclusion

    In elderly patients with community-acquired pneumonia complicated with T2DM, the pathogenic bacteria are mainly Gram-negative bacteria, with a high proportion of Klebsiella pneumoniae. The main Gram-positive bacteria are Staphylococcus aureus, and the proportion of fungi is on the rise. Pathogenic bacteria show different drug resistance to different drugs. Empirical treatment should avoid, the use of resistant antibiotics. Selective medication can be combined with their drug sensitivity tests to achieve better treatment outcomes.

  • Chao WANG, Yuan CHEN, Tiankai ZHOU, Hao LU, Chi CHEN, Junfei XU
    World Clinical Drug. 2026, 47(2): 203-208.

    Hashimoto thyroiditis(HT) is one of the most common autoimmune thyroid diseases in clinical practice. Spleen deficiency and Yin fire are key etiological factors and pathological mechanisms. Clinical treatment of HT based on the theory of Yin fire, with the therapeutic principles of raising spleen yang and descending Yin fire, which has demonstrated good efficacy. However, the underlying mechanisms remain unclear. This review summarizes recent research on traditional Chinese medicine(TCM) interventions for HT guided by the Yin fire theory, and discusses its effects and potential mechanisms to provide new insights for TCM treatment and future development of HT.

  • Fan XU, Qin SONG
    World Clinical Drug. 2026, 47(2): 209-212.

    B cell-activating factor(BAF) and a proliferation-inducing ligand play a crucial role in the development, survival and regulatory functions of B cells. B cells play a critical role in the pathogenesis of autoimmune disease(AID). Belimumab is a recombinant fully humanized immunoglobulin G2λ monoclonal antibody that specifically targets and binds to B lymphocyte stimulator factors, effectively inhibiting BAF activity. This action indirectly reduces B cell survival rates and the production of autoantibodies. This aritcle discussed the mechanism of action of belimumab and reviewed its latest advancements in AID such as systemic lupus erythematosus, autoimmune kidney disease, and primary Sjögren syndrome, aiming to provide a reference for clinical medication.

  • Zhiwei XIE, Ningling WANG, Kunlong ZHANG, Jinhua CHU, Linhai YANG
    World Clinical Drug. 2026, 47(1): 1-6.

    Pediatric chronic myelogenous leukemia(CML), a malignant hematopoietic stem cell disease driven by the BCR/ABL fusion gene. The emergence of tyrosine kinase inhibitor(TKI) has significantly improved long-term survival rates in children with CML, marking a milestone in its therapeutic history. However, TKI may exert long-term effects on pediatric growth and development, necessitating careful consideration of lifelong treatment tolerance and quality of life. The status of the second-generation TKI, dasatinib and nilotinib, in the first-line treatment of pediatric CML has been further clarified. The long-term value of imatinib has been precisely evaluated in specific populations. The novel agents like asciminib, which offer new avenues to overcome resistance. This review systematically summarized key recent progress in targeted therapy for pediatric CML, deeply analyzed the efficacy and safety profiles of each TKI generation,discussed individualized treatment selection strategies, and envisioned future directions guided by precision medicine and functional cure.

  • Zhujun WANG, Runming JIN
    World Clinical Drug. 2026, 47(1): 7-13.

    Anti-ganglioside(GD) 2 monoclonal antibodies have been widely used in clinical practice and can significantly improve the prognosis of children with high-risk neuroblastoma(HR-NB) and refractory/relapsed neuroblastoma(R/R NB). However, some patients still experience relapse, and a few develop severe treatment-related adverse reactions. Therefore, there is an urgent need to optimize GD2-targeted antibodies or explore new therapeutic targets to increase the cure rate of NB. This paper reviewed three aspects: the clinical application progress of GD2-related antibodies, the development of GD2 antibody-drug conjugates, and the research advances in novel antibody drugs for NB,aiming to provide references for clinical practice.

News